# ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

> **NCT04159896** · PHASE2 · TERMINATED · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 10 (actual)

## Conditions studied

- Castration Levels of Testosterone
- Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Carcinoma
- Prostate Carcinoma Metastatic in the Bone
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT04159896
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-13
- **Primary completion:** 2022-03-01
- **Final completion:** 2022-03-01
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** The study was closed to accrual on 3/1/21 due to safety concerns since 2 patients experienced CVA events.
- **Last updated:** 2024-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04159896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04159896, "ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04159896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*